Building on More Than 20 Years of Progress in Pancreatic Cancer Surveillance for High-Risk Individuals
Matthew B Yurgelun
J Clin Oncol . 2022 Jul 21;JCO2201287. doi: 10.1200/JCO.22.01287. Online ahead of print.
The vast majority of patients with pancreatic cancer (pancreatic ductal adenocarcinoma [PDAC]) are diagnosed in the unresectable and/or metastatic setting where 5-year survival is < 5%, although long-term cure is possible when PDAC is detected early.1,2 Individuals with inherited PDAC risk are thus ideal candidates in whom to study/develop surveillance strategies. Studies have shown that 4%-20% of individuals with PDAC harbor pathogenic germline variants (PGVs) in PDAC susceptibility genes (Table 1).4,11-18 Approximately 10% of individuals with PDAC have significant clustering of PDAC diagnoses in their family (usually without identifiable PGVs), which has been labeled familial pancreatic cancer.19
Read Full Article Here: https://doi.org/10.1200/jco.22.01287